Skip to main content
SpringerLink
Log in

Clonal haematopoiesis and atherosclerotic cardiovascular disease

  • Comment
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

Clonal haematopoiesis of indeterminate potential (CHIP) is defined as an expansion of mutant blood stem cells in individuals without haematological malignancies. CHIP is linked to an increased risk of non-cancerous disorders such as atherosclerotic cardiovascular disease, possibly because mutant innate immune cells have pro-inflammatory phenotypes. Prospective studies are needed to determine whether individuals with CHIP might benefit from anti-inflammatory therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Inflammation in cardiovascular disease.

References

  1. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat. Med. 27, 1921–1927 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lin, A. E., Rauch, P. J., Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis: confluence of malignant and nonmalignant diseases. Annu. Rev. Cancer Biol. 6, 187–200 (2022).

    Article  Google Scholar 

  5. Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

    Article  CAS  PubMed  Google Scholar 

  9. Svensson, E. C. et al. TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 7, 521–528 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sidlow, R. et al. The clinical challenge of clonal hematopoiesis, a newly recognized cardiovascular risk factor. JAMA Cardiol. 5, 958–961 (2020).

    Article  PubMed  Google Scholar 

  11. Swirski, F. K. From clonal haematopoiesis to the CANTOS trial. Nat. Rev. Cardiol. 15, 79–80 (2018).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Stanford University, Stanford, CA, USA

    Herra Ahmad

  2. Department of Cardiology, Charité Universitätsmedizin, Berlin, Germany

    Herra Ahmad

  3. Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA

    Siddhartha Jaiswal

  4. Institute for Stem Cell Biology & Regenerative Medicine, Stanford University, Stanford, CA, USA

    Siddhartha Jaiswal

Authors
  1. Herra Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siddhartha Jaiswal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siddhartha Jaiswal.

Ethics declarations

Competing interests

S.J. is a consultant to AVRO Bio, Foresite Labs, Novartis and Roche Genentech; reports speaking fees from GSK; is on the scientific advisory board of Bitterroot Bio; and is a founder, equity holder and on the scientific advisory board of TenSixteen Bio. H.A. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmad, H., Jaiswal, S. Clonal haematopoiesis and atherosclerotic cardiovascular disease. Nat Rev Cardiol 20, 437–438 (2023). https://doi.org/10.1038/s41569-023-00882-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41569-023-00882-2

  • Springer Nature Limited

This article is cited by

Search

Navigation